Physician profile
Ryan William Pappas
NPI 1235577065
$3,145.46
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $1,363 · 2021: $923 · 2022: $178 · 2023: $38.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $620.36 | 2020 | |
| Abbvie INC. | $427.50 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $275.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $137.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $118.00 | 2019-2021 | |
| Lundbeck LLC | $99.78 | 2020-2021 | |
| Allergan, INC. | $87.45 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $84.75 | 2019 | |
| Biogen, INC. | $75.39 | 2020-2021 | |
| Ucb, INC. | $74.82 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $72.25 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $66.95 | 2020-2021 | |
| Amgen INC. | $62.57 | 2020-2021 | |
| Genzyme Corporation | $61.56 | 2019-2020 | |
| Lilly USA, LLC | $60.50 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.31 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $50.66 | 2020-2021 | |
| Abbott Laboratories | $49.94 | 2021 | |
| Kyowa Kirin, INC. | $44.94 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $44.89 | 2021 | |
| Merz North America, INC. | $43.54 | 2020 | |
| Upsher-Smith Laboratories LLC | $42.31 | 2019-2021 | |
| Harmony Biosciences LLC | $41.79 | 2021 | |
| Assertio Therapeutics, INC. | $38.62 | 2020 | |
| Eisai INC. | $37.45 | 2021 | |
| Livanova USA, INC. | $35.10 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $34.68 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $34.43 | 2020 | |
| Zyla Life Sciences, INC. | $33.91 | 2019-2020 | |
| Neurelis, INC. | $30.61 | 2020-2021 | |
| Sk Life Science, INC. | $28.73 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $26.73 | 2021 | |
| Emd Serono, INC. | $24.45 | 2020-2021 | |
| Csl Behring | $23.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.10 | 2021 | |
| Almatica Pharma LLC | $18.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.82 | 2019 | |
| Greenwich Biosciences, INC. | $15.30 | 2020 | |
| Mdd US Operations, LLC | $13.40 | 2020 | |
| Owp Pharmaceuticals, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.